investing

Coronavirus Drugs Already in the Pipeline

It's not just chloroquine. Other existing medicines are being brought to bear against COVID-19. We look at what drugs have promise against COVID-19, and when they will get here.

What drugs will be available to treat COVID-19? Here's a quick rundown and a timeline for when to expect them. Note that these drugs have not been proven yet in trials of patients suffering from the novel coronavirus, and as such do not have official FDA approval, but they may still be helpful.

A lot of attention has been paid to existing antimalarials (in the chloroquine family) or flu drugs (favipiravir)

The antimalarials are in short supply, but production is ramping up. Mylan (MYL) and Teva Pharmaceuticals (TEVA) plan to jump-start production of hydroxychloroquine, which is also approved for treating lupus or rheumatoid arthritis. Teva says it will donate 6 million doses of hydroxychloroquine sulfate tablets tablets through wholesalers to hospitals by March 31. We expect them to be widely available in mid-April.

Remdesivir has been studied for years as an experimental antiviral, most recently for its potential against Ebola. Doctors were throwing it against COVID-19 in a "try something" approach, to the point that demand led its manufacturer, Gilead (GILD), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in mid-April, and two more in May.

One side effect of COVID-19 is a so-called "cytokine storm," in which the virus causes the immune system to overreact. Actemra by Roche (RHHBY) and Kevzara, by Sanofi (SNY) and Regeneron (REGN), are existing arthritis drugs which may also be able to counter a cytokine storm. Currently available, but starting testing for COVID-19 use.

Convalescent plasma, blood plasma from patients who have recovered from the virus, with their antibodies in it. Still in research, availability at least nine months away.

Artificial antibodies, which are similar to blood plasma but more consistent. Trials should begin in early summer, availability possible in the early fall. Companies working on this idea: Regeneron, Eli Lilly (LLY) with AbCellera, Vir Biotechnology (VIR), and Biogen (BIIB).

Most Popular

8 Money Tips for Seniors Suffering from Inflation
Inflation

8 Money Tips for Seniors Suffering from Inflation

This year has been an especially tough one for seniors on fixed incomes. To stay on track, try these eight financial survival tips.
June 26, 2022
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
An Easy Way to Find How Much You Will Spend in Retirement
retirement planning

An Easy Way to Find How Much You Will Spend in Retirement

One simple math equation can help you determine where to start building your retirement income plan, and whether your money should last.
June 27, 2022

Recommended

Move Over ETFs: Direct Indexing Is an Investment Strategy Worth Paying Attention to
investing

Move Over ETFs: Direct Indexing Is an Investment Strategy Worth Paying Attention to

More flexibility, more control, the potential for higher returns and tax-reducing strategies: With pros like that, could direct indexing be right for …
June 25, 2022
Taxes on Unemployment Benefits: A State-by-State Guide
state tax

Taxes on Unemployment Benefits: A State-by-State Guide

Don't be surprised by an unexpected state tax bill on your unemployment benefits. Know where unemployment compensation is taxable and where it isn't.
June 23, 2022
Smart Investing in a Bear Market
investing

Smart Investing in a Bear Market

Here's how to make the most of today’s dicey market.
June 22, 2022
Is the Stock Market Closed for Juneteenth?
Markets

Is the Stock Market Closed for Juneteenth?

In 2021, Washington passed legislation turning Juneteenth into a federal holiday. As a result, investors will have the day off Monday.
June 17, 2022